









| カタログ番号 | HB941026 |
|---|---|
| 説明 |
Bevacizumab (HB941026) is a research-grade recombinant antibody targeting Vascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG1-kappa |
| テスト済みアプリケーション | FCM |
| ターゲット | L-VEGF, N-VEGF, VEGF, VEGFA, VPF, Vascular endothelial growth factor A, long form, Vascular permeability factor |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | P15692 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | 12-IgG1, F(ab)-12IgG1, Fab-12IgG1, rhuMAb-VEGF, ABP215, 216974-75-3 |
| 背景 | Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin). 1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969 |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SEC-HPLC detection for Research Grade Bevacizumab.

Detects Human VEGF165 in indirect ELISAs.

Flow-cytometry using anti-human VEGFA antibody. U937 cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human VEGFA monoclonal antibody (Catalog HB941026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.

SDS-PAGE for Research Grade Bevacizumab

Flow-cytometry using FITC anti-human VEGFA antibody. U87 cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human VEGFA monoclonal antibody (Catalog: HB941026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.










+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206

中文
English
한국어
日本語
Español
Français
Русский